What transparency measure does the Act introduce?

• A. A country-of-origin label for all imported drugs
• B. A disclosure of clinical trial results
• C. A requirement to publish drug prices
• D. A label for packaging only

Answer: (A)

This item tests transparency in the pharmaceutical supply chain by making the origin of imported drugs visible. Requiring a country-of-origin label for all imported drugs ensures that stakeholders—pharmacists, regulators, and patients—can see exactly where a product came from, which supports authentication, traceability, and regulatory compliance. It helps detect counterfeit or misrepresented products and improves recall and safety actions across the distribution network.

Disclosures of clinical trial results, publishing drug prices, or labeling packaging only address different kinds of transparency—research data, pricing information, or packaging details—not the origin and provenance of imported drugs. So the country-of-origin labeling is the best fit for the transparency measure described.